siRNA for the Treatment of SARS-CoV-2

Development of therapeutic agents for severe acute respiratory syndrome (SARS) viral infection using short interfering RNA (siRNA) inhibitors exemplifies a powerful new means to combat the recently emerging SARS-CoV-2. Integrated processes within Creative Biolabs’ siRNA drug development platform provide a total solution for siRNA therapeutics discovery and development, from siRNA design, synthesis to preclinical tests. With our advanced siRNA core technologies and manufacturing infrastructure, Creative Biolabs is the ideal partner for different industries currently working on the development of siRNA therapeutics for SARS-CoV-2.

siRNA and Coronaviruses

RNA interference in animals is mediated by small double-stranded RNA molecules, siRNA. siRNAs can be used as tools to study single gene function both in vivo and in vitro and are an attractive new class of therapeutics. The siRNA delivery systems are categorized as viral delivery systems and non-viral delivery systems such as peptide, polymers and lipids. Numerous studies with synthetic or plasmid-encoded endogenously expressed siRNA provide evidence that siRNA has an antiviral effect against various viruses, including SARS-CoV. The reported siRNA agents are potent both for prophylactic and therapeutic treatment of SARS infection, and they lack toxicity in Rhesus macaque model.

Fig.1 Overview of different siRNA strategies. (Reynolds, 2017)

Why Creative Biolabs?

In addition to nucleoside analogues, guanosine analogue, adenosine analogue, siRNA molecules may also provide a new approach to therapy for SARS-CoV-2. Creative Biolabs has designed a series of siRNAs targeting different sites of the SARS-CoV-2 to inhibit coronaviruses-induced cell death. We focused on several regions of the SARS-CoV-2 genome, the leader sequence, transcription-regulating sequence (TRS), 3’-UTR, the coding sequence for the spike protein and RNA-dependent RNA polymerase (RdRp) to design specific siRNAs. Based on previous research and the successful experience of siRNA aimed at SARS-CoV, we designed a series of siRNAs that were appropriate in length and had a G/C content of 30-50%. Creative Biolabs also provides deeper characterization of the siRNA about its effect, biophysical characters and cellular activities.

At Creative Biolabs, our featured discovery solutions eliminate challenges and generate better drug candidates faster. Our team will work with you to design experiments and get the results you need to make critical decisions and advance your projects. No one else offers the same collaborative approach or generates high-quality data faster. If you are interested in our siRNA inhibitors development services for SARS-CoV-2, please feel free to contact us for more information.

Reference

1. Reynolds, N.; et al. Polymers in the Delivery of siRNA for the Treatment of Virus Infections. Polymeric Gene Delivery Systems. Springer, Cham, 2017: 287-328.

For Research Use Only. We do not provide direct services or products for patients.